How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,088 results for

Depo Provera

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

341. A Safety and Efficacy Study of Daikenchuto (TU-100) to Relieve Abdominal Bloating in Female Subjects With Irritable Bowel Syndrome

suitable forms of contraception throughout the study and for 30 days after the last dose i.e., hormonal contraceptives (such as oral contraceptives, Depo-Provera, NuvaRing, Essure), condoms used with a spermicide, an intrauterine device, or abstinence. Females are not considered to be of childbearing potential if they are naturally postmenopausal (no menses for at least 1 year and, if < 55 years of age, have a documented follicle-stimulating hormone [FSH] level of ≥ 35 mIU/mL) or have documentation

2014 Clinical Trials

342. Addition of Liraglutide to Patients With Type 2 Diabetes Treated With Multiple Daily Insulin Injections

or multiple endocrine neoplasia syndrome type 2 (MEN2) Screening calcitonin values greater than 14.6 pmol/l. Females of childbearing potential who are pregnant, breast-feeding or intend to become pregnant or are not using adequate contraceptive methods (adequate contraceptive measures as required by local law or practice; accepted methods: oral contraceptive pills, depo provera contraceptive injections, implanted contraceptive, transdermal patch, intrauterine device, vasectomized partner, or abstinence

2014 Clinical Trials

343. Combination Alexandrite Laser and Topical Therapy vs Topical Therapy Alone for Treatment of Melasma

urine pregnancy test at the beginning of the study, and agree to practice appropriate birth-control to prevent pregnancy during the study. The type and dose of birth control must have been stable for at least 3 months prior to study entry and it is not expected to change during the study; acceptable methods of birth control are oral contraceptives, contraceptive patches/rings/implants Norplant®, Depo-Provera®, double-barrier methods (e.g. condoms and spermicide), abstinence and vasectomies

2014 Clinical Trials

344. Phase 1A/1B Study of PSA/IL-2/GM-CSF Vaccine for Recurrent Prostate Cancer in Hormone Naive and Hormone Independent Patients

investigational therapy. Acceptable birth control options include: a) surgical sterilization (subject and/or subject's partner), b) approved hormonal contraceptives or therapies (such as birth control pills, Depo-Provera, or Lupron Depot), c) barrier methods (such as a condom or diaphragm) used with a spermicide, and d) an intrauterine device (IUD). Exclusion Criteria: Presence of documented neuroendocrine differentiation on the original pathology report Evidence of metastatic disease Immune compromised

2014 Clinical Trials

345. A Study to Investigate the Pharmacokinetics and Safety of Beclomethasone Dipropionate Administered by Breath-Actuated Inhaler and Metered-Dose Inhaler in Healthy Adults

), or injectable progesterone (Depo-Provera®, Pfizer Inc., or equivalent) double barrier methods (condoms, cervical cap, diaphragm, and vaginal contraceptive film with spermicide) intrauterine device (IUD) with a low failure rate defined as less than 1% per year monogamous with a vasectomized male partner or same-sex female partner or is of childbearing potential and not sexually active, has a negative serum pregnancy test, and is willing to commit to using a consistent and acceptable method of birth control

2014 Clinical Trials

346. Postcoital Testing Study of the SILCS Diaphragm Used With 3% N-9 Gel, ContraGel, or No Gel

pregnancy outcome. Note: If recently pregnant must have had at least two spontaneous menses since pregnancy outcome Current use of any hormonal contraceptive or a copper IUD, or use of Depo-Provera in the last 120 days Currently breastfeeding or having breastfed an infant in the last two months, or planning to breastfeed during the course of the study Significant gynecological abnormalities (including abnormal vaginal bleeding or excessive vaginal discharge) Device does not appropriately fit volunteer

2014 Clinical Trials

347. Cytokines and Vascular Inflammation in Psoriasis

; Hormonal contraception (oral, intramuscular, implant or transdermal) which include Depo-Provera, Evra and Nuvaring; Intrauterine device (IUD); Female patients of childbearing potential must have a negative serum pregnancy test at the Screening visit. Patient is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, physical examination, and Chest X-Ray (CXR) performed at Screening. Patient will be evaluated

2014 Clinical Trials

348. Transdermal or Oral Telapristone Acetate in Treating Patients Undergoing Mastectomy

of skin invasion by the breast cancer, or inflammatory changes with skin edema AND erythema Women with skin diseases (psoriasis, eczema) A history of thromboembolic disorder or cerebral vascular disease Use of oral contraceptives or other hormonal treatments within eight weeks prior to the randomization or during the period of the study; women should not have used Depo-Provera in the preceding 6 months; use of hormone coated IUD like Mirena is allowed Participants may not have received any other

2014 Clinical Trials

349. Dose-ranging Efficacy of Polydextrose Supplement on Colonic Transit Time and Symptoms in Adults With Functional Constipation

a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System), Intrauterine devices, Double barrier method, Vasectomy of partner (shown successful as per appropriate follow-up), Tubal ligation, and Non

2014 Clinical Trials

350. Pharmacokinetic Study of MTC896 Gel in Subjects With Acne

year, or are abstinent; (Acceptable methods of birth control are defined as: abstinence, oral contraceptives, contraceptive patches/implants; Depo-Provera®, double barrier methods (eg, condom and spermicide) or an IUD. Birth control method must have been stable/unchanged for 12 weeks prior to Baseline and must remain unchanged during study participation); If male, has been vasectomized or agrees to use an accepted method of birth control with female partner during study participation and for 30

2014 Clinical Trials

351. Does Meal Timing Affect Energy Expenditure

, lung or nervous system disease Have stomach or intestinal problems Regularly use medications such as steroids, beta blockers, adrenergic-stimulating agents, and laxatives Take any medications or supplements known to affect sleep, circadian rhythms, or metabolism (with the exception that certain forms of birth control are allowed) Have abnormal lab work that is clinically significant in the opinion of the study physician Are pregnant or lactating Take the Depo Provera shot, or use an Interuterine

2014 Clinical Trials

352. A Safety and Tolerability Study of Crenolanib in Combination With Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia Patients With FLT3 Mutations

for laboratory used) or bilateral oophorectomy or radiation castration and amenorrheic for at least 3 months or with bilateral tubal ligation WOCBP must practice contraception. Acceptable methods of contraception are double barrier methods (condoms with spermicidal jelly or foam and diaphragm with spermicidal jelly or foam), oral, depo provera, or injectable contraceptives, intrauterine devices, tubal ligations, and abstention Male patients (except those with prior surgical contraceptive procedures

2014 Clinical Trials

353. Phase I One-month Safety, PK, PD, and Acceptability Study of IVR Releasing TFV and LNG or TFV Alone

, sign an informed consent form and comply with study procedures as required by the protocol Exclusion Criteria: History of hysterectomy Currently pregnant or within two calendar months from the last pregnancy outcome. Note: If recently pregnant must have had at least two spontaneous menses since pregnancy outcome. Use of any hormonal contraceptive method in the last 3 months (oral, transdermal, transvaginal, implant, or hormonal intrauterine contraceptive device) Injection of Depo-Provera

2014 Clinical Trials

354. Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers

pharmacological contraceptive (including oral, patch or injectable contraceptives) within 1 month prior to study Day 0 and for the duration of the study. Use of Depo-Provera is excluded for six months prior to study Day 0 Use of hormone replacement therapy within 1 month prior to study Day 0 and for the duration of the study Administration of antibiotics within 10 days prior to study Day 0 (Visit 2) or during the trial History of acute illness within sixty (60) days of study Day 0. Subjects are excluded

2014 Clinical Trials

355. [Trial of device that is not approved or cleared by the U.S. FDA]

potential who is pregnant or intending to become pregnant or breast-feeding, or is not using adequate contraceptive methods. Acceptable contraception includes birth control pill / patch / vaginal ring, Depo-Provera, Norplant, an IUD, the double barrier method (the woman uses a diaphragm and spermicide and the man uses a condom), or abstinence. Any cardiovascular disease, defined as a clinically significant EKG abnormality at the time of screening or any history of: stroke, heart failure, myocardial

2014 Clinical Trials

356. A Clinical Trial of Fel d 1 Peptide Immunotherapy

duration of the study including washout periods; Vasectomised sexual partner (with appropriate post-vasectomy documentation of the absence of sperm in ejaculate) + male condom; Tubal occlusion + male condom; Intrauterine device (IUD), provided coils are copper banded + male condom; Intrauterine system (IUS) Levonorgestrel, e.g. Mirena + male condom; Medroxyprogesterone injections (Depo-Provera) + male condom; Etonogestrel implants (e.g. Implanon, Norplant) + male condom; Normal and low dose combined

2014 Clinical Trials

357. A Phase 2, Study to Evaluate the Safety and Efficacy Proellex® (Telapristone Acetate) Administered Vaginally in the Treatment of Uterine Fibroids

testosterone, progestin, androgen, estrogen, anabolic steroids, DHEA or hormonal products for at least 2 weeks prior to screening and during the study Use of oral contraceptives in the preceding 30 days. Use of Depo-Provera® in the preceding 10 months. Use of GnRHas (e.g. Lupron Depot) within 3 months of the first dose of study drug (Lupron Depot must have a wash-out period of 3 months) Has an IUD in place Known or suspected carcinoma of the breast or reproductive organs Recent history (within past 6

2014 Clinical Trials

358. Investigating the Effects of Glucodiaâ„¢ on Glucose Parameters, Triglycerides and Body Weight

a hysterectomy or oophorectomy, bilateral tubal ligation or are post-menopausal (natural or surgically with > 1 year since last menstruation). OR Female subject of childbearing potential must agree to use a medically approved method of birth control and have a negative urine pregnancy test result. Acceptable methods of birth control include: Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo (...) -Provera, Lunelle), or hormone implant (Norplant System), Double-barrier method (condoms with spermicide or diaphragm with spermacide), Non-hormonal intrauterine devices, Vasectomy of partner, Non-heterosexual lifestyle Subjects who have no plans to change their smoking habits during the trial period. Subjects who are normally active and are deemed to be healthy by the Medical Director Subjects who agree to maintain their current level of activity throughout the trial period. Subjects who agree

2014 Clinical Trials

359. Safety and Efficacy of Generic Diclofenac Epolamine Acute Pain Due to Minor Ankle Sprain

. For the purpose of this study the following are considered acceptable methods of birth control: oral or injectable contraceptives, contraceptive patches, Depo-Provera® (on stable treatment for at least 3 months) NuvaRing® (vaginal contraceptive); Implanon™ (contraceptive implant) double barrier methods (e.g. condom and spermicide), intrauterine device, or abstinence with a 2nd acceptable method of birth control, should the patient become sexually active. A sterile sexual partner is NOT considered an adequate

2014 Clinical Trials

360. Study to Assess the Incidence of Hemolysis, Safety, and Efficacy of Tafenoquine (SB-252263, WR238605) Versus Primaquine in Subjects With Plasmodium Vivax Malaria

as defined below. Use of an intrauterine device with a documented failure rate of <1% per year; Use of depo provera injection; Double barrier method consisting of spermicide with either condom or diaphragm; Male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female. Complete abstinence from intercourse for 2 weeks prior to administration of study medication, throughout the study and for a period of 90 days after stopping study medication

2014 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>